🟢 Neumora Therapeutics is trading 7% up in pre-market as the reason remains unclear

Neumora Therapeutics is trading at $0.47, up 6.91%, with no confirmed explanation for its pre-market rise.

• No confirmed company announcement explaining the gain was identified; the latest listed company release predates this session.
• A report said Wall Street Zen cut its rating to Strong Sell, but did not establish that change as the cause. Major indices are mixed, and available evidence does not clearly link the gain to broad-market sentiment.